Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "50" vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
Hydrochlorothiazide 50 mg orally once daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hydrochlorothiazide is not extensively metabolized. Reserpine is metabolized primarily in the liver by CYP450 enzymes.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
90-96% (primarily to albumin and alpha1-acid glycoprotein)
Approximately 70-80% bound to plasma proteins, primarily albumin.
200-400 L/kg (extremely large due to extensive tissue binding, especially in adrenergic nerve terminals)
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 40-50% (extensive first-pass metabolism)
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in anuria. For GFR 30-60 m L/min: reduce dose to 25 mg daily. For GFR <30 m L/min: not recommended.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: no adjustment. Child-Pugh B/C: use with caution; monitor electrolytes and renal function; reduce dose if needed.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not typically recommended; safety and efficacy not established.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate at 12.5-25 mg orally once daily; titrate cautiously; monitor electrolytes and renal function.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Electrolyte imbalance (especially hypokalemia),Sulfonamide allergy (hydrochlorothiazide),Mental depression (reserpine),Bradycardia and arrhythmias (reserpine)
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Anuria,Known sulfonamide allergy (hydrochlorothiazide),History of mental depression (reserpine),Active peptic ulcer or ulcerative colitis (reserpine),Electroconvulsive therapy (reserpine)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid high-sodium foods (e.g., processed meats, canned soups) to prevent fluid retention and counteract antihypertensive effects. Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) as thiazides cause potassium loss; however, reserpine may not affect potassium levels. Limit alcohol intake. Take with food or milk to reduce gastrointestinal upset.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association with congenital anomalies not established. Second and third trimesters: May cause fetal or neonatal electrolyte disturbances, hypoglycemia, and decreased placental perfusion. Reserpine: First trimester: Animal studies show no teratogenic effects, human data insufficient. Second and third trimesters: May cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to depletion of catecholamines.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Hydrochlorothiazide: Excreted into human milk in small amounts; M/P ratio approximately 0.2. Reserpine: Excreted into breast milk; M/P ratio not well established. Both are considered compatible with breastfeeding by most authorities, but use caution as reserpine may cause gastrointestinal disturbances, nasal congestion, and lethargy in the infant. Monitor infant for side effects.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Hydrochlorothiazide: Dose adjustment not typically required for pharmacokinetic changes, but use lowest effective dose due to risk of decreased placental perfusion. Reserpine: No specific dose adjustment recommended for pregnancy. Monitor for hypotension and avoid use near term to reduce neonatal adverse effects.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Hydrochlorothiazide 50 mg plus reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause depression; avoid in patients with history of depression. Onset of antihypertensive effect is 3-6 hours. Use with caution in patients with renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug may make you dizzy; avoid driving or operating machinery until you know how it affects you.,Reserpine can cause nasal congestion, drowsiness, or depression; contact your doctor if you experience mood changes.,Avoid alcohol as it may increase dizziness and drowsiness.,Stay hydrated but do not overhydrate; report excessive thirst, dry mouth, or muscle cramps.,Do not stop taking this medication abruptly as it may cause a rapid increase in blood pressure.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,This medication may increase your sensitivity to sunlight; use sunscreen and protective clothing.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "50" vs ALDOCLOR-150, answered by our medical review team.
HYDRO-SERP "50" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "50" and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "50" is: Hydrochlorothiazide 50 mg orally once daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "50" and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "50" is classified as Category C. Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association wi. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.